HK1247105A1 - Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型 - Google Patents

Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型 Download PDF

Info

Publication number
HK1247105A1
HK1247105A1 HK18106740.0A HK18106740A HK1247105A1 HK 1247105 A1 HK1247105 A1 HK 1247105A1 HK 18106740 A HK18106740 A HK 18106740A HK 1247105 A1 HK1247105 A1 HK 1247105A1
Authority
HK
Hong Kong
Prior art keywords
opioid
dosage form
combination dosage
receptor antagonist
release
Prior art date
Application number
HK18106740.0A
Other languages
English (en)
Chinese (zh)
Inventor
Shaoling Li
Manshiu Leung
Hao Zhang
Venkat R. Thalladi
Yun Mo
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of HK1247105A1 publication Critical patent/HK1247105A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18106740.0A 2015-04-02 2016-03-31 Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型 HK1247105A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141981P 2015-04-02 2015-04-02
US62/141,981 2015-04-02
PCT/US2016/025176 WO2016161069A1 (en) 2015-04-02 2016-03-31 Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Publications (1)

Publication Number Publication Date
HK1247105A1 true HK1247105A1 (zh) 2018-09-21

Family

ID=55806767

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106740.0A HK1247105A1 (zh) 2015-04-02 2016-03-31 Mu类鸦片受体拮抗剂与类鸦片药剂的组合剂型

Country Status (27)

Country Link
US (4) US20160287573A1 (enExample)
EP (1) EP3277278B1 (enExample)
JP (2) JP6713483B2 (enExample)
KR (1) KR20170132325A (enExample)
CN (1) CN107820424B (enExample)
AU (1) AU2016243691A1 (enExample)
BR (1) BR112017021120A2 (enExample)
CA (1) CA2980328A1 (enExample)
CY (1) CY1122828T1 (enExample)
DK (1) DK3277278T3 (enExample)
ES (1) ES2774473T3 (enExample)
HK (1) HK1247105A1 (enExample)
HR (1) HRP20200432T1 (enExample)
HU (1) HUE048785T2 (enExample)
IL (1) IL254593A0 (enExample)
LT (1) LT3277278T (enExample)
ME (1) ME03671B (enExample)
MX (1) MX2017012474A (enExample)
PH (1) PH12017501767A1 (enExample)
PL (1) PL3277278T3 (enExample)
PT (1) PT3277278T (enExample)
RS (1) RS60074B1 (enExample)
RU (1) RU2017134794A (enExample)
SI (1) SI3277278T1 (enExample)
SM (1) SMT202000157T1 (enExample)
TW (1) TW201642856A (enExample)
WO (1) WO2016161069A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3277278B1 (en) 2015-04-02 2020-01-08 Theravance Biopharma R&D IP, LLC Combination dosage form of a mu opioid receptor antagonist and an opioid agent
WO2019031560A1 (ja) * 2017-08-08 2019-02-14 日本合成化学工業株式会社 医薬錠剤、およびその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
DK1414451T3 (da) * 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
AU2004314693B2 (en) 2003-09-26 2011-04-07 Alza Corporation Drug coating providing high drug loading and methods for providing the same
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
AU2006218603A1 (en) * 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CN101395154B (zh) * 2006-03-01 2011-01-19 施万制药 作为μ阿片受体拮抗剂的8-氮杂双环[3.2.1]辛烷化合物
CN101500542A (zh) * 2006-07-11 2009-08-05 共有药物有限公司 控释制剂
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
AU2009244190B2 (en) * 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
MX2011011919A (es) * 2009-05-12 2012-01-27 Bpsi Holdings Llc Sistemas de recubrimiento de pelicula de liberacion inmediata con barrera contra humedad mejorada y sustratos recubiertos con dichos sistemas.
IT1398930B1 (it) * 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
AU2011295837B2 (en) * 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
ES2801725T3 (es) 2011-02-01 2021-01-12 Bristol Myers Squibb Co Formulaciones farmacéuticas que incluyen un compuesto de amina
US9339489B2 (en) * 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
EP3277278B1 (en) 2015-04-02 2020-01-08 Theravance Biopharma R&D IP, LLC Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Also Published As

Publication number Publication date
HRP20200432T1 (hr) 2020-06-12
SMT202000157T1 (it) 2020-05-08
RS60074B1 (sr) 2020-05-29
SI3277278T1 (sl) 2020-04-30
US20180050028A1 (en) 2018-02-22
US20210161884A1 (en) 2021-06-03
US11452723B2 (en) 2022-09-27
IL254593A0 (en) 2017-11-30
DK3277278T3 (da) 2020-04-06
EP3277278B1 (en) 2020-01-08
KR20170132325A (ko) 2017-12-01
ES2774473T3 (es) 2020-07-21
HUE048785T2 (hu) 2020-08-28
ME03671B (me) 2020-10-20
US10369142B2 (en) 2019-08-06
PT3277278T (pt) 2020-04-16
WO2016161069A1 (en) 2016-10-06
CY1122828T1 (el) 2021-05-05
TW201642856A (zh) 2016-12-16
US10946009B2 (en) 2021-03-16
EP3277278A1 (en) 2018-02-07
JP2018513138A (ja) 2018-05-24
US20160287573A1 (en) 2016-10-06
MX2017012474A (es) 2018-01-11
RU2017134794A (ru) 2019-04-04
US20190321350A1 (en) 2019-10-24
CN107820424A (zh) 2018-03-20
LT3277278T (lt) 2020-03-25
BR112017021120A2 (pt) 2018-07-03
JP6713483B2 (ja) 2020-06-24
JP2020073583A (ja) 2020-05-14
PH12017501767A1 (en) 2018-06-11
CA2980328A1 (en) 2016-10-06
PL3277278T3 (pl) 2020-07-27
AU2016243691A1 (en) 2017-10-12
CN107820424B (zh) 2020-07-28

Similar Documents

Publication Publication Date Title
ZA201904616B (en) Glp-1 receptor agonists and uses thereof
IL247854B (en) Muscarinic receptor antagonists, preparations containing them and their uses
SI3453707T1 (sl) Benzazepinski derivati, postopek priprave, farmacevtski sestavek in uporaba le-teh
WO2015095423A3 (en) Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MX2017006320A (es) Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
SG11201608372PA (en) Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof
EP3638205A4 (en) DEVICES AND METHODS FOR ADMINISTERING THERAPEUTICS
HUE047106T2 (hu) Eljárás gyógyászatilag alkalmazható víz elõállítására, nevezetesen injekcióhoz való vízhez (WFI), és készülék az eljárás végrehajtására
EP3223793A4 (en) Compositions and methods for delivering a bio-active agent or bio-active agents
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
PH12017501767A1 (en) Combination dosage form of a mu opioid receptor antagonist and an opioid agent
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
EP3144005A4 (en) Composition for preventing and treating male infertility, containing mixed herbal extract as active ingredient and use thereof
PT3490535T (pt) Composição de libertação sustentada compreendendo tolcapona micronizada
EP4420734A3 (en) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
EP3233825A4 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
HK40024596A (en) Corticotropin releasing factor receptor antagonists
HK40016029A (en) Corticotropin releasing factor receptor antagonists
IL258514B (en) Nanoparticles, preparation and system for administering 5fu and their uses
HK40027644A (en) Devices and methods for delivering therapeutics
AU2015902112A0 (en) Agonists and antagonists for protease activated receptor 2 (PAR2)
AU2016902769A0 (en) Release agent composition
ZA201504398B (en) Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof
AU2016901231A0 (en) Release agent composition
AU2015902665A0 (en) Peptidyl tpor antagonists and uses thereof